OKMETIC OYJ STOCK EXCHANGE RELEASE 8 OCTOBER 2013 AT 1.00 P.M. PUBLISHING OF OKMETIC'S Q3/2013 INTERIM REPORT ON 24 OCTOBER 2013 Okmetic Oyj will publish its interim report for January-September 2013 on Thursday, 24 October 2013 approximately at 8 a.m. Finnish time (EEST). A briefing for analysts, investors and media will take place on the same day at 8.30 a.m. in Helsinki Stock Exchange building, Fabianinkatu 14, Helsinki (2nd floor, entrance via NASDAQ OMX's reception). The result will be presented by President Kai Seikku. Participants are kindly requested to register by email to communications@okmetic.com or by telephone to +358 9 5028 0269/Tuuli Oja. OKMETIC OYJ Juha Jaatinen Senior Vice President, Finance, IT, and Communications For further information, please contact: Senior Vice President, Finance, IT, and Communications Juha Jaatinen, Okmetic Oyj, tel. +358 9 5028 0286, email: juha.jaatinen@okmetic.com Distribution: NASDAQ OMX Helsinki Principal media www.okmetic.com OKMETIC IN BRIEF Take it higher Okmetic is a technology company which supplies tailor-made silicon wafers for sensor and semiconductor industries and sells its technological expertise. Okmetic provides its customers with solutions that boost their competitiveness and profitability. Okmetic's silicon wafers are part of a further processing chain that produces end products that improve human interaction and quality of life. Okmetic's products are based on high-tech expertise that generates added value for customers, innovative product development and an extremely efficient production process. Okmetic has a global customer base and sales network, production plants in Finland and the US and contract manufacturers in Japan and China. Okmetic's shares are listed on NASDAQ OMX Helsinki under the code OKM1V. For more information on the company, please visit our website at www.okmetic.com. [HUG#1734229]
PUBLISHING OF OKMETIC'S Q3/2013 INTERIM REPORT ON 24
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Sarepta Therapeutics Faces Legal Scrutiny Amid Regulatory Challenges
Legal Challenges for Sarepta Therapeutics The situation regarding Sarepta Therapeutics is becoming increasingly complex. Recently, a pending securities class action was initiated due to unsettling news about safety concerns linked to their medication, ELEVIDYS. This product aims to treat Duchenne muscular dystrophy, a severe condition affecting young boys. As the company...
Continue Reading
Enhancing Landscape Operations: LandCare's Partnership with Lytx+™
LandCare Enhances Operational Efficiencies with Lytx+ LandCare, a leading commercial landscaping company in the nation, has made significant strides in its operations by adopting the innovative Lytx+™ solution in conjunction with Geotab. This collaboration aims to optimize fleet safety and management, ensuring that LandCare continues to thrive in a competitive...
Continue Reading
Grand Sierra Resort Launches Ambitious $1 Billion Arena Project
Grand Sierra Resort Unveils Major Arena Development Grand Sierra Resort (GSR) has officially broken ground on a groundbreaking new arena, marking the first phase of an extensive $1 billion redevelopment project that is set to forever change the landscape of Reno. This ambitious undertaking is the largest private investment in the history of the region, signaling a bright...
Continue Reading
Saba Capital Management Adjusts Holdings in Eaton Vance Trust
Saba Capital Management Modifies Its Holdings in Eaton Vance Trust Saba Capital Management, L.P., a significant player in the investment management sector, has recently garnered attention by adjusting its position in the Eaton Vance California Municipal Income Trust (NYSE: CEV). This strategic decision involved the sale of 44,367 shares, accumulating over $484,725 over...
Continue Reading
Key Insights on Treatt Plc's Market Dealing Activities
Understanding the Amendment for Treatt Plc The recent amendment related to Treatt Plc has sparked interest in financial circles, especially among shareholders and market analysts. This document outlines public dealing disclosures from an exempt principal trader acting on behalf of a clientele, primarily concerning Treatt Plc, a prominent player in the flavor and fragrance...
Continue Reading